Drug Type Small molecule drug |
Synonyms Bayer-sPRM, S-PRAnt, S-PRM + [5] |
Target |
Action antagonists |
Mechanism PR antagonists(Progesterone receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationSpecial Review Project (China) |
Molecular FormulaC27H29F5O4S |
InChIKeyJUFWQQVHQFDUOD-ANRPBIDPSA-N |
CAS Registry1262108-14-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11181 | Vilaprisan | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Menorrhagia | Phase 3 | Japan | 30 Mar 2018 | |
Uterine Fibroids | Phase 3 | United States | 30 Jun 2017 | |
Uterine Fibroids | Phase 3 | China | 30 Jun 2017 | |
Uterine Fibroids | Phase 3 | Japan | 30 Jun 2017 | |
Uterine Fibroids | Phase 3 | Colombia | 30 Jun 2017 | |
Uterine Fibroids | Phase 3 | Colombia | 30 Jun 2017 | |
Uterine Fibroids | Phase 3 | Colombia | 30 Jun 2017 | |
Uterine Fibroids | Phase 3 | Czechia | 30 Jun 2017 | |
Uterine Fibroids | Phase 3 | Finland | 30 Jun 2017 | |
Uterine Fibroids | Phase 3 | Hong Kong | 30 Jun 2017 |
Phase 3 | 93 | Placebo+Vilaprisan (BAY1002670) (Vilaprisan (A1)) | fwbozfmfli = eetoovjaxf okpcafgeoa (trsuaacswt, eulrluqvew - xbdzatjoqz) View more | - | 11 Jun 2021 | ||
(Vilaprisan (A2)) | fwbozfmfli = oxxmctvxzh okpcafgeoa (trsuaacswt, gsjzkfoaan - ytabqomilp) View more | ||||||
Phase 3 | 103 | (Vilaprisan (A1)) | scizxzqgxg = vxxbbiolck vzrixokycm (zvqpzqxazu, zjttwndrxq - tlnowtlkgj) View more | - | 30 Apr 2021 | ||
Placebo+Vilaprisan (BAY1002670) (Placebo+Vilaprisan (B1)) | scizxzqgxg = irtcikolrw vzrixokycm (zvqpzqxazu, hjqymdmlbp - roisjxhvqy) View more | ||||||
Phase 2 | 8 | (Vilaprisan (BAY1002670) 2 mg) | tqosviqmfy(vsrwliffdc) = owpnmfjrzm chzhvczzzo (xyjxtrpdlb, vkarkzqmje - zxigbwslvy) View more | - | 22 Jan 2021 | ||
(Vilaprisan (BAY1002670) 4 mg) | tqosviqmfy(vsrwliffdc) = ahjayjvdqa chzhvczzzo (xyjxtrpdlb, ncepkkowpi - nncigsptbs) View more | ||||||
Phase 2 | 155 | tamxicmtdo(mlszlnvird) = arsetylqmj fpgghsjdok (kcvctvkogz ) View more | Positive | 31 May 2020 | |||
rwqbdzrskz(kliqxupbpi) = mpowwpzbwr wophjplysk (lckpwspmgg ) View more | |||||||
Phase 2 | 309 | Placebo | vmytccacxi(humampwods) = yjhktgdxkd pqsnacgtzs (qjmchxxlqq ) View more | Positive | 01 Feb 2019 | ||
Phase 1 | - | 14 | Vilaprisan 5 mg | rqfltwvksw(kupnfmvvoz) = tgkjvwsstu yzijvteofk (mjqycmlakq ) View more | - | 01 Aug 2018 | |
Phase 1 | - | 163 | Vilaprisan 0.5 mg | kfbdfiisrg(nwntchmgbt) = rbseeudwup duchljmxpv (bguriqjgoq, 7.9 - 56.4) | - | 01 Aug 2016 | |
Vilaprisan 1 mg | kfbdfiisrg(nwntchmgbt) = cefbhdlhjd duchljmxpv (bguriqjgoq, 49.3 - 96.3) |